Overton ET, Richmond G, Rizzardini G, Thalme A, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2M, a randomized, open-label, Phase 3b, noninferiority study. Clin Infect Dis 2023 Jan 20:ciad020. doi: 10.1093.
PMID: 36660819